Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) traded up 2.3% on Friday . The company traded as high as $148.94 and last traded at $148.66, with a volume of 92,971 shares changing hands. The stock had previously closed at $145.25.

A number of equities research analysts have recently weighed in on the company. Wedbush reissued a “buy” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a research note on Saturday, July 9th. Cantor Fitzgerald initiated coverage on Intercept Pharmaceuticals in a report on Wednesday, July 6th. They set a “sell” rating and a $58.00 price target on the stock. Robert W. Baird restated an “outperform” rating and set a $332.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, June 15th. Needham & Company LLC restated a “buy” rating and set a $350.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, June 1st. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Tuesday, May 31st. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $203.08.

The firm’s 50-day moving average is $148.61 and its 200-day moving average is $133.95. The stock’s market cap is $3.68 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.60) by $1.57. During the same quarter in the previous year, the company earned ($1.78) EPS. Equities analysts predict that Intercept Pharmaceuticals Inc. will post ($16.82) earnings per share for the current fiscal year.

In other news, CEO Mark Pruzanski sold 714 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Lisa Bright sold 251 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total transaction of $34,512.50. Following the sale, the insider now directly owns 18,855 shares of the company’s stock, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

Other hedge funds recently bought and sold shares of the company. California State Teachers Retirement System increased its stake in Intercept Pharmaceuticals by 1.4% in the fourth quarter. California State Teachers Retirement System now owns 29,529 shares of the biopharmaceutical company’s stock valued at $4,410,000 after buying an additional 400 shares in the last quarter. Rhumbline Advisers raised its position in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Intercept Pharmaceuticals by 5.9% in the fourth quarter. ProShare Advisors LLC now owns 20,213 shares of the biopharmaceutical company’s stock valued at $3,019,000 after buying an additional 1,130 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares during the last quarter. Finally, South Dakota Investment Council raised its position in shares of Intercept Pharmaceuticals by 6.8% in the fourth quarter. South Dakota Investment Council now owns 36,200 shares of the biopharmaceutical company’s stock valued at $5,406,000 after buying an additional 2,300 shares during the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.